Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Summary

This was a multi-center, randomized, placebo-controlled, participant-and-investigator-blinded, sponsor open-label study in obese participants with or without Type 2 Diabetes Mellitus.

Timeline

Start

2022-02-10

Primary completion

2023-05-11

Completion

2023-05-11

Outcome

Outcome not reported

Stopped: “The tolerability to benefit ratio based on maximum weight loss observed was not considered favorable at the doses studied and the study was terminated early”

Drugs

Indications